Switch theme
Sign up to access all valuation multiples
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
1946
137
LTM Revenue $57.6M
LTM EBITDA $5.5M
$85.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apontis Pharma has a last 12-month revenue (LTM) of $57.6M and a last 12-month EBITDA of $5.5M.
In the most recent fiscal year, Apontis Pharma achieved revenue of $54.4M and an EBITDA of $4.0M.
Apontis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apontis Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.6M | XXX | $54.4M | XXX | XXX | XXX |
| Gross Profit | $57.6M | XXX | $31.1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $5.5M | XXX | $4.0M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $2.9M | XXX | $1.4M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $1.8M | XXX | $0.8M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Apontis Pharma's stock price is EUR 11 (or $12).
Apontis Pharma has current market cap of EUR 91.2M (or $102M), and EV of EUR 75.8M (or $85.1M).
See Apontis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85.1M | $102M | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Apontis Pharma has market cap of $102M and EV of $85.1M.
Apontis Pharma's trades at 1.6x EV/Revenue multiple, and 21.3x EV/EBITDA.
Equity research analysts estimate Apontis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apontis Pharma has a P/E ratio of 57.5x.
See valuation multiples for Apontis Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV (current) | $85.1M | XXX | $85.1M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 15.4x | XXX | 21.3x | XXX | XXX | XXX |
| EV/EBIT | 29.4x | XXX | 59.9x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 57.5x | XXX | 121.0x | XXX | XXX | XXX |
| EV/FCF | -11.8x | XXX | -14.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApontis Pharma's last 12 month revenue growth is 17%
Apontis Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Apontis Pharma's rule of 40 is -17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apontis Pharma's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Apontis Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 102% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -17% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apontis Pharma acquired XXX companies to date.
Last acquisition by Apontis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Apontis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Apontis Pharma founded? | Apontis Pharma was founded in 1946. |
| Where is Apontis Pharma headquartered? | Apontis Pharma is headquartered in Germany. |
| How many employees does Apontis Pharma have? | As of today, Apontis Pharma has 137 employees. |
| Is Apontis Pharma publicy listed? | Yes, Apontis Pharma is a public company listed on FRA. |
| What is the stock symbol of Apontis Pharma? | Apontis Pharma trades under APPH ticker. |
| When did Apontis Pharma go public? | Apontis Pharma went public in 2021. |
| Who are competitors of Apontis Pharma? | Similar companies to Apontis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Apontis Pharma? | Apontis Pharma's current market cap is $102M |
| What is the current revenue of Apontis Pharma? | Apontis Pharma's last 12 months revenue is $57.6M. |
| What is the current revenue growth of Apontis Pharma? | Apontis Pharma revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Apontis Pharma? | Current revenue multiple of Apontis Pharma is 1.5x. |
| Is Apontis Pharma profitable? | Yes, Apontis Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apontis Pharma? | Apontis Pharma's last 12 months EBITDA is $5.5M. |
| What is Apontis Pharma's EBITDA margin? | Apontis Pharma's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Apontis Pharma? | Current EBITDA multiple of Apontis Pharma is 15.4x. |
| What is the current FCF of Apontis Pharma? | Apontis Pharma's last 12 months FCF is -$7.2M. |
| What is Apontis Pharma's FCF margin? | Apontis Pharma's last 12 months FCF margin is -13%. |
| What is the current EV/FCF multiple of Apontis Pharma? | Current FCF multiple of Apontis Pharma is -11.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
